Key Takeaways
- • Illinois passed HB 5000 (May 28, 2026) expanding healthcare transaction reporting requirements, mandating Attorney General consent for certain private equity deals in healthcare sectors, strengthening state-level oversight of M&A activity.
- • SB 712 establishes corporate practice of medicine (CPOM) rules for applied behavior analysis (ABA) services, limiting clinical decision-making authority to licensed behavior analysts (BCBAs) and effective January 2027, directly restricting private equity ownership structures in autism therapy providers.
- • Private equity firms have acquired approximately 80% of ABA service centers over a four-year span (2018–2022), targeting the sector due to scalability through client acquisition and practice consolidation, while Medicaid spending on autism services continues to rise alongside increased childhood autism diagnoses.
- • ABA represents the most widely mandated and intensive autism treatment across state insurance coverage, making it a primary target for private equity investment seeking recurring Medicaid reimbursement streams; however, PE-backed providers face regulatory pressure to maintain service quality and clinical standards.
- • Illinois joins California, Massachusetts, and Texas in introducing comprehensive legislation targeting private equity corporate structures in healthcare, signaling a coordinated multi-state legislative shift toward limiting financial engineering in essential health services.
Summary
Illinois lawmakers have enacted two major legislative measures targeting private equity involvement in healthcare delivery, with particular focus on applied behavior analysis (ABA) services for autism treatment. HB 5000, passed by both chambers on May 28, 2026, expands transaction reporting requirements and mandates Attorney General consent for certain healthcare mergers and acquisitions involving private equity operators. This represents an enhancement to Illinois' existing mini-Hart-Scott-Rodino Act framework, creating a regulatory moat around consolidation activity in the state's healthcare infrastructure.
SB 712 establishes corporate practice of medicine restrictions specifically for ABA service providers, a direct response to private equity's systematic acquisition of autism therapy centers. The legislation limits clinical decision-making authority exclusively to licensed behavior analysts (BCBAs), effectively preventing non-clinical private equity ownership structures from controlling patient care protocols. The statute takes effect January 2027, providing a six-month implementation window for existing PE-backed ABA operators to restructure their ownership or governance models.
The legislative activity reflects mounting concern over private equity's expansion into autism services. Between 2018 and 2022, private equity firms acquired approximately 80% of ABA service centers across the United States, capitalizing on the sector's inherent scalability and the fact that ABA is the only autism treatment universally mandated by state insurance coverage. PE investors have been particularly attracted to ABA providers because clinical services can be expanded through increasing client volume or service hours at existing locations, or through roll-up acquisition strategies consolidating individual practices into multi-site platforms. As childhood autism diagnoses continue to increase nationwide, state Medicaid spending on intensive ABA therapy—which represents the most widely recognized evidence-based treatment for autism spectrum disorder—has become a significant budget line item.
Concerns about private equity's financial engineering in healthcare have prompted a coordinated multi-state legislative response. California, Massachusetts, Texas, and Illinois have all introduced or advanced legislation targeting PE corporate structures in health services, signaling institutional investor concern that cost-reduction initiatives may compromise service quality, staff training, and clinical supervision standards. The Illinois measures represent some of the most specific restrictions, focusing directly on both transactional oversight and clinical governance rather than blanket prohibitions.
SB 712 establishes corporate practice of medicine restrictions specifically for ABA service providers, a direct response to private equity's systematic acquisition of autism therapy centers. The legislation limits clinical decision-making authority exclusively to licensed behavior analysts (BCBAs), effectively preventing non-clinical private equity ownership structures from controlling patient care protocols. The statute takes effect January 2027, providing a six-month implementation window for existing PE-backed ABA operators to restructure their ownership or governance models.
The legislative activity reflects mounting concern over private equity's expansion into autism services. Between 2018 and 2022, private equity firms acquired approximately 80% of ABA service centers across the United States, capitalizing on the sector's inherent scalability and the fact that ABA is the only autism treatment universally mandated by state insurance coverage. PE investors have been particularly attracted to ABA providers because clinical services can be expanded through increasing client volume or service hours at existing locations, or through roll-up acquisition strategies consolidating individual practices into multi-site platforms. As childhood autism diagnoses continue to increase nationwide, state Medicaid spending on intensive ABA therapy—which represents the most widely recognized evidence-based treatment for autism spectrum disorder—has become a significant budget line item.
Concerns about private equity's financial engineering in healthcare have prompted a coordinated multi-state legislative response. California, Massachusetts, Texas, and Illinois have all introduced or advanced legislation targeting PE corporate structures in health services, signaling institutional investor concern that cost-reduction initiatives may compromise service quality, staff training, and clinical supervision standards. The Illinois measures represent some of the most specific restrictions, focusing directly on both transactional oversight and clinical governance rather than blanket prohibitions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.